If Abbvie’s Allergan gets its way, the biggest threat to its blockbuster wrinkle remover Botox — Evolus’s Jeuveau — will be banned from the U.S. for the next 10 years.
Allergan and its Korean partner Medytox have asked the U.S. International Trade Commission to ban Jeuveau — manufactured by Korea’s Daewoong Pharmaceuticals and sold in the U.S. by Evolus — because of trade secret theft. According to their complaint, Daewoong obtained the bacteria Medytox uses to develop Botox from a former Medytox employee, a claim both Daewoong and the former employee deny. But an ITC administrative law judge ruled in favor of Allergan and Medytox in July, recommending a 10-year ban on Jeuveau.
ITC to Decide Botox Trade Secret Battle
This is an atrociously incorrect legal ruling. The legal battle is about patent infringement in KOREA, not the US. The ITC has NO JURISDICTION about a patent infringement in KOREA.